We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Showcases Solutions for Laboratories of the Future

By LabMedica International staff writers
Posted on 30 Jul 2024
Print article
Image: Roche’s booth at ADLM 2024 provides a view of the future of laboratory and point-of-care diagnostics (Photo courtesy of Roche)
Image: Roche’s booth at ADLM 2024 provides a view of the future of laboratory and point-of-care diagnostics (Photo courtesy of Roche)

Roche (Basel, Switzerland) is showcasing a laboratory of the future exhibit at the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo. Attendees can experience how Roche's growing portfolio of integrated systems and data solutions optimizes resources and simplifies and streamlines operations while driving better health outcomes.

Focusing on key attributes of science-based leadership, operational simplicity, and patient-centric partnership, Roche is featuring its newest innovations in-booth at ADLM. These include the future cobas Mass Spec solution designed to be a total end-to-end solution for clinical mass spectrometry testing with the goal of seamless integration into the routine laboratory. Roche is also highlighting the new CCM Vertical, a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas connection modules. Also featuring at ADLM 2024 is the cobas liat system which brings gold-standard PCR technology to the point of care, providing results within 20 minutes across a growing menu of assays.

The cobas pure integrated solutions which combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs are also being highlighted at the meeting. Additionally, Roche is featuring the cobas eplex system, a rapid syndromic molecular diagnostic solution that has been updated with new features across all aspects of the workflow process, alongside the cobas 5800 is a compact, fully automated molecular PCR-testing solution with a comprehensive menu of assays. Visitors to the Roche booth can also experience the cobas LightCycler PRO qPCR system which is designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories with an improved user experience.

At ADLM 2024, Roche is also presenting its full array of navify digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. Roche is also presenting eight Roche Idea Lab segments in its booth, where experts will discuss topics such as mass spectrometry, digital solutions, respiratory testing, and the use of high-medical-value assays when treating Alzheimer's and heart failure. Scientific industry workshops include "Laboratorians' Perspectives on Evaluation and Implementation of Alzheimer's CSF Assays" and "Making a Subjective Sepsis Diagnosis More Objective: The Role of AI-based Sepsis Medical Algorithms in Empowering Healthcare Decisions."

"Laboratorians strive to deliver trusted, timely test results to patients with greater effectiveness and efficiency. Our latest generation of cobas solutions are proven to deliver seamless integration of systems and data to support these efforts," said Brad Moore, president and CEO of Roche Diagnostics North America. "We are excited to share these next-generation solutions, which are the building blocks for future laboratories, and are eager to partner with our customers so that they can both do more with less and deliver the best possible outcomes for patients."

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Celiac Disease Test
AESKULISA tTg-A New Generation

Print article

Channels

Molecular Diagnostics

view channel
Image: Low levels of a protein that signals placental development could alert physicians to the need for enhanced monitoring (Photo courtesy of Shutterstock)

Blood Test Could Identify Expectant Mothers at Risk of Preterm Delivery

Early preterm birth, defined as delivery before 34 weeks of gestation, carries significant risks for adverse health outcomes. However, there is no universal screening strategy available, which limits the... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.